Vanda Pharmaceuticals Inc.
VNDAUS売上高
$216M
百万USD
営業利益
$-151M
百万USD
純利益
$-220M
百万USD
ROE
-67.4%
最新FY
EPS
$-3.74
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $63M | $9M | $0.15 |
| FY2021 | Q2 | $68M | $10M | $0.17 |
| FY2021 | Q3 | $70M | $8M | $0.14 |
| FY2021 | FY | $269M | $33M | $0.58 |
| FY2022 | Q1 | $60M | $-6M | $-0.11 |
| FY2022 | Q2 | $64M | $3M | $0.05 |
| FY2022 | Q3 | $65M | $3M | $0.06 |
| FY2022 | FY | $254M | $6M | $0.11 |
| FY2023 | Q1 | $62M | $3M | $0.06 |
| FY2023 | Q2 | $46M | $2M | $0.03 |
| FY2023 | Q3 | $39M | $0M | $0.00 |
| FY2023 | FY | $193M | $3M | $0.04 |
| FY2024 | Q1 | $47M | $-4M | $-0.07 |
| FY2024 | Q2 | $50M | $-5M | $-0.08 |
| FY2024 | Q3 | $48M | $-5M | $-0.09 |
| FY2024 | FY | $199M | $-19M | $-0.33 |
| FY2025 | Q1 | $50M | $-29M | $-0.50 |
| FY2025 | Q2 | $53M | $-27M | $-0.46 |
| FY2025 | Q3 | $56M | $-23M | $-0.38 |
| FY2025 | FY | $216M | $-220M | $-3.74 |
| FY2026 | Q1 | $52M | $-49M | $-0.82 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $193M | $227M | $248M | $269M | $254M | $193M | $199M | $216M |
| 営業利益 | $-19M | $-17M | $22M | $23M | $27M | $42M | $6M | $-14M | $-41M | $-151M |
| 純利益 | $-18M | $-16M | $25M | $116M | $23M | $33M | $6M | $3M | $-19M | $-220M |
| 総資産 | $210M | $205M | $332M | $484M | $533M | $594M | $634M | $648M | $656M | $489M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $131M | $131M | $275M | $411M | $453M | $505M | $527M | $545M | $539M | $327M |
| 営業CF | - | - | - | $46M | $52M | $64M | $32M | $13M | $-16M | $-109M |
| EPS | $-0.41 | $-0.35 | $0.48 | $2.11 | $0.42 | $0.58 | $0.11 | $0.04 | $-0.33 | $-3.74 |
| BPS | $2.96 | $2.89 | $5.23 | $7.66 | $8.26 | $9.03 | $9.28 | $9.47 | $9.23 | $5.54 |
| ROE | -13.7% | -11.8% | 9.2% | 28.1% | 5.1% | 6.6% | 1.2% | 0.5% | -3.5% | -67.4% |